当前位置： SCI文献检索 > MOLECULAR CANCER THERAPEUTICS期刊下所有文献 > Photodynamic therapy mediates the oxygen-independent activation of hypoxia-inducible factor 1alpha.

Photodynamic therapy mediates the oxygen-independent activation of hypoxia-inducible factor 1alpha.

Abstract：

:Photodynamic therapy (PDT) induces the expression of the hypoxia-inducible factor 1alpha (HIF-1alpha) subunit of the HIF-1 transcription factor and its target genes in vitro and in vivo. PDT also induces the expression of the enzyme cyclooxygenase-2 and its metabolite, prostaglandin E2 (PGE2). PGE2 and hypoxia act independently and synergistically to increase HIF-1alpha accumulation and nuclear translocation. To examine the expression of HIF-1 target genes in response to PDT-mediated oxidative stress and PGE2 under normoxic conditions, we established EMT6 cells transfected with a plasmid consisting of a hypoxia response element promoter and a downstream gene encoding for green fluorescent protein (GFP). To examine the temporal kinetics of HIF-1alpha nuclear translocation in response to PDT, we transfected a second line of EMT6 cells with a GFP-tagged HIF-1alpha fusion vector. Cell monolayers were incubated with 1 microg mL(-1) Photofrin for 24 h and irradiated with fluences of 1, 2.5, and 5 J cm(-2). Direct measurement of oxygen concentration during irradiation confirmed that cells remained well oxygenated. Cells were also exposed to 1 and 10 micromol/L PGE2 for 3 h. In normoxic conditions, Photofrin, PDT, and PGE2 treatment activated HIF-1alpha and induced its nuclear translocation. Maximal Photofrin-PDT-mediated HIF-1alpha activation was intermediate in magnitude between that induced by PGE2 and that by the hypoxia mimic cobalt chloride. This work establishes that PDT induces significant activation of the HIF-1alpha pathway in the absence of hypoxia and supports the interpretation that the induction of HIF-1 target genes by PDT may be mediated, at least in part, by the prostaglandin pathway.

journal_name

Mol Cancer Ther

journal_title

Molecular cancer therapeutics

authors

Mitra S,Cassar SE,Niles DJ,Puskas JA,Frelinger JG,Foster TH

doi

10.1158/1535-7163.MCT-06-0421

subject

Has Abstract

pub_date

2006-12-01 00:00:00

pages

3268-74

issue

12

eissn

1535-7163

issn

1538-8514

pii

5/12/3268

journal_volume

5

pub_type

杂志文章

相关文献

MOLECULAR CANCER THERAPEUTICS文献大全
  • High doses of tyrosine kinase inhibitor PTK787 enhance the efficacy of ischemic hypoxia for the treatment of hepatocellular carcinoma: dual effects on cancer cell and angiogenesis.

    abstract：:The present study aimed to investigate the therapeutic efficacy of combining vascular endothelial growth factor (VEGF) receptor blockade using tyrosine kinase inhibitor PTK787 with hypoxia for the treatment of hepatocellular carcinoma (HCC). The in vivo effects of the treatments were determined in a rat orthotopic HCC...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-06-0149

    authors： Yang ZF,Poon RT,Liu Y,Lau CK,Ho DW,Tam KH,Lam CT,Fan ST

    更新日期：2006-09-01 00:00:00

  • PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer.

    abstract：:PHA-739358 is a small-molecule 3-aminopyrazole derivative with strong activity against Aurora kinases and cross-reactivities with some receptor tyrosine kinases relevant for cancer. PHA-739358 inhibits all Aurora kinase family members and shows a dominant Aurora B kinase inhibition-related cellular phenotype and mecha...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-07-0444

    authors： Carpinelli P,Ceruti R,Giorgini ML,Cappella P,Gianellini L,Croci V,Degrassi A,Texido G,Rocchetti M,Vianello P,Rusconi L,Storici P,Zugnoni P,Arrigoni C,Soncini C,Alli C,Patton V,Marsiglio A,Ballinari D,Pesenti E,Fan

    更新日期：2007-12-01 00:00:00

  • Inhibition of TRIP1/S8/hSug1, a component of the human 19S proteasome, enhances mitotic apoptosis induced by spindle poisons.

    abstract：:Mitotic spindle poisons (e.g., Taxol and vinblastine), used as chemotherapy drugs, inhibit mitotic spindle function, activate the mitotic spindle checkpoint, arrest cells in mitosis, and then cause cell death by mechanisms that are poorly understood. By expression cloning, we identified a truncated version of human TR...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-05-0126

    authors： Yamada HY,Gorbsky GJ

    更新日期：2006-01-01 00:00:00

  • MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma.

    abstract：:Genomic analyses of squamous cell carcinoma (SCC) have yet to yield significant strategies against pathway activation to improve treatment. Platinum-based chemotherapy remains the mainstay of treatment for SCC of different histotypes either as a single-agent or alongside other chemotherapeutic drugs or radiotherapy; h...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-15-0062

    authors： Kong LR,Chua KN,Sim WJ,Ng HC,Bi C,Ho J,Nga ME,Pang YH,Ong WR,Soo RA,Huynh H,Chng WJ,Thiery JP,Goh BC

    更新日期：2015-07-01 00:00:00

  • Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft

    abstract：OBJECTIVE:Targeting the tumor vasculature may offer an alternative or complementary therapeutic approach to targeting growth factor signaling in lung cancer. The aim of these studies was to evaluate the antitumor effects in vivo of the combination of ZD6126, a tumor-selective vascular-targeting agent; ZD1839 (gefitinib...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：

    authors： Raben D,Bianco C,Damiano V,Bianco R,Melisi D,Mignogna C,D'Armiento FP,Cionini L,Bianco AR,Tortora G,Ciardiello F,Bunn P

    更新日期：2004-08-01 00:00:00

  • A novel indolocarbazole, ICP-1, abrogates DNA damage-induced cell cycle arrest and enhances cytotoxicity: similarities and differences to the cell cycle checkpoint abrogator UCN-01.

    abstract：:DNA damaging agents such as cisplatin arrest cell cycle progression at either G1, S, or G2 phase, although the G1 arrest is only seen in cells expressing the wild-type p53 tumor suppressor protein. We have reported that 7-hydroxystaurosporine (UCN-01) overcomes S and G2 phase arrest and enhances the cytotoxicity of ci...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：

    authors： Eastman A,Kohn EA,Brown MK,Rathman J,Livingstone M,Blank DH,Gribble GW

    更新日期：2002-10-01 00:00:00

  • p37 Induces tumor invasiveness.

    abstract：:Previous studies have shown a statistically significant correlation between human carcinomas and monoclonal antibody detection of a Mycoplasma hyorhinis-encoded protein known as p37. A potential mechanism of p37 is that it might promote invasion and metastasis. Recombinant p37 enhanced the invasiveness of two prostate...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-05-0040

    authors： Ketcham CM,Anai S,Reutzel R,Sheng S,Schuster SM,Brenes RB,Agbandje-McKenna M,McKenna R,Rosser CJ,Boehlein SK

    更新日期：2005-07-01 00:00:00

  • Induction of Thioredoxin-Interacting Protein by a Histone Deacetylase Inhibitor, Entinostat, Is Associated with DNA Damage and Apoptosis in Esophageal Adenocarcinoma.

    abstract：:In 2017, an estimated 17,000 individuals were diagnosed with esophageal adenocarcinoma (EAC), and less than 20% will survive 5 years. Positron emission tomography avidity is indicative of high glucose utilization and is nearly universal in EAC. TXNIP blocks glucose uptake and exhibits proapoptotic functions. Higher ex...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-17-1240

    authors： Feingold PL,Surman DR,Brown K,Xu Y,McDuffie LA,Shukla V,Reardon ES,Crooks DR,Trepel JB,Lee S,Lee MJ,Gao S,Xi S,McLoughlin KC,Diggs LP,Beer DG,Nancarrow DJ,Neckers LM,Davis JL,Hoang CD,Hernandez JM,Schrump DS,R

    更新日期：2018-09-01 00:00:00

  • Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells.

    abstract：:The present studies have determined whether interactions between the cyclin-dependent kinase inhibitor flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA; vorinostat; Zolinza) occur in breast cancer cells. MDA-MB-231 and MCF7 cells were treated with flavopiridol (25-100 nmol/L) an...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-07-0561

    authors： Mitchell C,Park MA,Zhang G,Yacoub A,Curiel DT,Fisher PB,Roberts JD,Grant S,Dent P

    更新日期：2007-12-01 00:00:00

  • The Indenoisoquinoline LMP517: A Novel Antitumor Agent Targeting both TOP1 and TOP2.

    abstract：:The camptothecin derivatives topoisomerase I (TOP1) inhibitors, irinotecan and topotecan, are FDA approved for the treatment of colorectal, ovarian, lung and breast cancers. Because of the chemical instability of camptothecins, short plasma half-life, drug efflux by the multidrug-resistance ABC transporters, and the s...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-19-1064

    authors： Marzi L,Sun Y,Huang SN,James A,Difilippantonio S,Pommier Y

    更新日期：2020-08-01 00:00:00

  • DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma.

    abstract：:Antibody-drug conjugates (ADC), potent cytotoxic drugs linked to antibodies via chemical linkers, allow specific targeting of drugs to neoplastic cells. We have used this technology to develop the ADC DCDT2980S that targets CD22, an antigen with expression limited to B cells and the vast majority of non-Hodgkin lympho...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-12-1173

    authors： Li D,Poon KA,Yu SF,Dere R,Go M,Lau J,Zheng B,Elkins K,Danilenko D,Kozak KR,Chan P,Chuh J,Shi X,Nazzal D,Fuh F,McBride J,Ramakrishnan V,de Tute R,Rawstron A,Jack AS,Deng R,Chu YW,Dornan D,Williams M,Ho W,

    更新日期：2013-07-01 00:00:00

  • Keratin down-regulation in vimentin-positive cancer cells is reversible by vimentin RNA interference, which inhibits growth and motility.

    abstract：:At later stages of tumor progression, epithelial carcinogenesis is associated with transition to a mesenchymal phenotype, which may contribute to the more aggressive properties of cancer cells and may be stimulated by growth factors such as epidermal growth factor and transforming growth factor-beta. Previously, we fo...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-08-0450

    authors： Paccione RJ,Miyazaki H,Patel V,Waseem A,Gutkind JS,Zehner ZE,Yeudall WA

    更新日期：2008-09-01 00:00:00

  • Targeting multiple key signaling pathways in melanoma using leelamine.

    abstract：:Melanoma is a highly drug-resistant cancer with resistance developing to agents targeting single proteins. To circumvent this problem, a new class of agent inhibiting multiple key pathways important in this disease is being developed to reduce the likelihood of developing resistant disease. The phosphoinositide 3-kina...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-13-0867

    authors： Gowda R,Madhunapantula SV,Kuzu OF,Sharma A,Robertson GP

    更新日期：2014-07-01 00:00:00

  • Targeting Peroxisome Proliferator-Activated Receptor γ to Increase Estrogen-Induced Apoptosis in Estrogen-Deprived Breast Cancer Cells.

    abstract：:Peroxisome proliferator-activated receptor γ (PPARγ) is an important transcription factor that modulates lipid metabolism and inflammation. However, it remains unclear whether PPARγ is involved in modulation of estrogen (E2)-induced inflammation, thus affecting apoptosis of E2-deprived breast cancer cells, MCF-7:5C an...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-18-0088

    authors： Fan P,Abderrahman B,Chai TS,Yerrum S,Jordan VC

    更新日期：2018-12-01 00:00:00

  • Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines.

    abstract：:Human epidermal growth factor receptor-2 (HER2) and epidermal growth factor receptor (EGFR) heterodimerize to activate mitogenic signaling pathways. We have shown previously, using MCF7 subcloned cell lines with graded levels of HER2 expression, that responsiveness to trastuzumab and AG1478 (an anti-EGFR agent), varie...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-07-0079

    authors： Emlet DR,Brown KA,Kociban DL,Pollice AA,Smith CA,Ong BB,Shackney SE

    更新日期：2007-10-01 00:00:00

  • Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma.

    abstract：:Multiple myeloma remains incurable and the majority of patients die within 5 years of diagnosis. Reolysin, the infusible form of human reovirus (RV), is a novel viral oncolytic therapy associated with antitumor activity likely resulting from direct oncolysis and a virus-mediated antitumor immune response. Results from...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-15-0240-T

    authors： Stiff A,Caserta E,Sborov DW,Nuovo GJ,Mo X,Schlotter SY,Canella A,Smith E,Badway J,Old M,Jaime-Ramirez AC,Yan P,Benson DM,Byrd JC,Baiocchi R,Kaur B,Hofmeister CC,Pichiorri F

    更新日期：2016-05-01 00:00:00

  • Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse.

    abstract：:R-roscovitine (seliciclib, CYC202) is a cyclin-dependent kinase inhibitor currently in phase II clinical trials in patients with cancer. Here, we describe its mouse metabolism and pharmacokinetics as well as the identification of the principal metabolites in hepatic microsomes, plasma, and urine. Following microsomal ...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：

    authors： Nutley BP,Raynaud FI,Wilson SC,Fischer PM,Hayes A,Goddard PM,McClue SJ,Jarman M,Lane DP,Workman P

    更新日期：2005-01-01 00:00:00

  • Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines.

    abstract：:Insulin-like growth factor-I receptor (IGF-IR) is an important mediator of tumor cell survival and shows prognostic significance in sarcoma. To explore potential therapeutic strategies for interrupting signaling through this pathway, we assessed the ability of cyclolignan picropodophyllin (PPP), a member of the cyclol...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-09-0115

    authors： Duan Z,Choy E,Harmon D,Yang C,Ryu K,Schwab J,Mankin H,Hornicek FJ

    更新日期：2009-08-01 00:00:00

  • Gene expression profiles in a panel of childhood leukemia cell lines mirror critical features of the disease.

    abstract：:The development of new drugs against cancer requires established cell lines. They are needed for in vitro studies to identify candidate drugs and in xenograft models to measure drug efficacy in vivo. Specific criteria need to be fulfilled by cell lines used in the evaluation of potential novel therapeutic agents. It i...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：

    authors： Kees UR,Ford J,Watson M,Murch A,Ringńer M,Walker RL,Meltzer P

    更新日期：2003-07-01 00:00:00

  • Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival.

    abstract：:We reported previously a significant increase in survival of nude rats harboring orthotopic A549 human non-small cell lung cancer tumors after treatment with a combination of exisulind (Sulindac Sulfone) and docetaxel (D. C. Chan, Clin. Cancer Res., 8: 904-912, 2002). The purpose of the current study was to determine ...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：

    authors： Whitehead CM,Earle KA,Fetter J,Xu S,Hartman T,Chan DC,Zhao TL,Piazza G,Klein-Szanto AJ,Pamukcu R,Alila H,Bunn PA Jr,Thompson WJ

    更新日期：2003-05-01 00:00:00

  • A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer.

    abstract：:Mutations in ERK signaling drive a significant percentage of malignancies. LY3009120, a pan-RAF and dimer inhibitor, has preclinical activity in RAS- and BRAF-mutated cell lines including BRAF-mutant melanoma resistant to BRAF inhibitors. This multicenter, open-label, phase I clinical trial (NCT02014116) consisted of ...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章,多中心研究

    doi：10.1158/1535-7163.MCT-19-0681

    authors： Sullivan RJ,Hollebecque A,Flaherty KT,Shapiro GI,Rodon Ahnert J,Millward MJ,Zhang W,Gao L,Sykes A,Willard MD,Yu D,Schade AE,Crowe K,Flynn DL,Kaufman MD,Henry JR,Peng SB,Benhadji KA,Conti I,Gordon MS,Tiu RV,Hong

    更新日期：2020-02-01 00:00:00

  • A review of trabectedin (ET-743): a unique mechanism of action.

    abstract：:Trabectedin (ET-743) is a marine alkaloid isolated from the Caribbean tunicate Ecteinascidia turbinata, with a chemical structure characterized by three fused tetrahydroisoquinoline rings. Two of these rings (subunits A and B) provide the framework for covalent interaction with the minor groove of the DNA double helix...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章,评审

    doi：10.1158/1535-7163.MCT-10-0263

    authors： D'Incalci M,Galmarini CM

    更新日期：2010-08-01 00:00:00

  • The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice.

    abstract：:CEP-7055, a fully synthetic, orally active N,N-dimethylglycine ester of CEP-5214, a C3-(isopropylmethoxy)-fused pyrrolocarbazole with potent pan-vascular endothelial growth factor receptor (VEGFR) kinase inhibitory activity, has recently completed phase I clinical trials in cancer patients. These studies evaluated the...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-05-0327

    authors： Jones-Bolin S,Zhao H,Hunter K,Klein-Szanto A,Ruggeri B

    更新日期：2006-07-01 00:00:00

  • Epidermal growth factor-like domain 7 predicts response to first-line chemotherapy and bevacizumab in patients with metastatic colorectal cancer.

    abstract：:The number of approved antiangiogenic drugs is constantly growing and emphasizes the need for predictive biomarkers. The aim of this study was to analyze the predictive value of epidermal growth factor-like domain 7 (EGFL7) and microRNA-126 (miR126) to first-line chemotherapy combined with bevacizumab, in patients wit...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章,随机对照试验

    doi：10.1158/1535-7163.MCT-14-0131

    authors： Hansen TF,Nielsen BS,Sørensen FB,Johnsson A,Jakobsen A

    更新日期：2014-09-01 00:00:00

  • Antagonism of VEGF by genetically engineered dendritic cells is essential to induce antitumor immunity against malignant ascites.

    abstract：:Malignant ascitis (MA) is a highly intractable and immunotherapy-resistant state of advanced gastrointestinal and ovarian cancers. Using a murine model of MA with CT26 colon cancer cells, we here determined that the imbalance between the VEGF-A/vascular permeability factor and its decoy receptor, soluble fms-like tryr...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-10-0479

    authors： Sugiyama M,Kakeji Y,Tsujitani S,Harada Y,Onimaru M,Yoshida K,Tanaka S,Emi Y,Morita M,Morodomi Y,Hasegawa M,Maehara Y,Yonemitsu Y

    更新日期：2011-03-01 00:00:00

  • Acridine Derivatives as Inhibitors of the IRE1α-XBP1 Pathway Are Cytotoxic to Human Multiple Myeloma.

    abstract：:Using a luciferase reporter-based high-throughput chemical library screen and topological data analysis, we identified N-acridine-9-yl-N',N'-dimethylpropane-1,3-diamine (DAPA) as an inhibitor of the inositol requiring kinase 1α (IRE1α)-X-box binding protein-1 (XBP1) pathway of the unfolded protein response. We designe...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-15-1023

    authors： Jiang D,Tam AB,Alagappan M,Hay MP,Gupta A,Kozak MM,Solow-Cordero DE,Lum PY,Denko NC,Giaccia AJ,Le QT,Niwa M,Koong AC

    更新日期：2016-09-01 00:00:00

  • Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas.

    abstract：:Histone modification has emerged as a promising approach to cancer therapy. We explored the efficacy of a novel class of histone deacetylase inhibitors in the treatment of malignant gliomas. Treatment of glioma cell lines with two butyric acid derivatives, pivaloylomethyl butyrate (AN-9) and butyroyloxymethyl butyrate...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-05-0087

    authors： Entin-Meer M,Rephaeli A,Yang X,Nudelman A,VandenBerg SR,Haas-Kogan DA

    更新日期：2005-12-01 00:00:00

  • In vivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities.

    abstract：:Nanotechnology has enabled significant advances in the areas of cancer diagnosis and therapy. The field of drug delivery is a sterling example, with nanoparticles being increasingly used for generating therapeutic formulations of poorly water-soluble, yet potent anticancer drugs. Whereas a number of nanoparticle-drug ...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-08-0476

    authors： Bisht S,Feldmann G,Koorstra JB,Mullendore M,Alvarez H,Karikari C,Rudek MA,Lee CK,Maitra A,Maitra A

    更新日期：2008-12-01 00:00:00

  • Generation of a canine anti-EGFR (ErbB-1) antibody for passive immunotherapy in dog cancer patients.

    abstract：:Passive immunotherapy with monoclonal antibodies represents a cornerstone of human anticancer therapies, but has not been established in veterinary medicine yet. As the tumor-associated antigen EGFR (ErbB-1) is highly conserved between humans and dogs, and considering the effectiveness of the anti-EGFR antibody cetuxi...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-13-0288

    authors： Singer J,Fazekas J,Wang W,Weichselbaumer M,Matz M,Mader A,Steinfellner W,Meitz S,Mechtcheriakova D,Sobanov Y,Willmann M,Stockner T,Spillner E,Kunert R,Jensen-Jarolim E

    更新日期：2014-07-01 00:00:00

  • Trastuzumab-Resistant HER2+ Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition.

    abstract：:HER2-targeted therapies, such as trastuzumab, have increased the survival rates of HER2+ breast cancer patients. However, despite these therapies, many tumors eventually develop resistance to these therapies. Our lab previously reported an unexpected sensitivity of HER2+ breast cancer cells to poly (ADP-ribose) polyme...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-17-0302

    authors： Wielgos ME,Zhang Z,Rajbhandari R,Cooper TS,Zeng L,Forero A,Esteva FJ,Osborne CK,Schiff R,LoBuglio AF,Nozell SE,Yang ES

    更新日期：2018-05-01 00:00:00